Healius Ltd
HLS
Company Profile
Business description
Healius is Australia’s second-largest pathology provider and third-largest diagnostic imaging provider, though the latter business is set to be sold in early 2025. Pathology and imaging revenue is almost entirely earned via the public health Medicare system. Healius typically earns approximately 75% of revenue from pathology and 25% from diagnostic imaging.
Contact
Sector
Healthcare
Stock type
Industry
Diagnostics & Research
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Undervalued ASX share announces plan to create shareholder value
The market cheers update from the company.
stocks
Ask the analyst: Why have Healius shares struggled so much?
Shares in Australia's second biggest pathology operator have floundered in recent years. Shane Ponraj thinks better days could be ahead.
stocks
Top-rated funds love these 3 cheap ASX shares
These companies could offer good value and, as of the latest data and have the stamp of approval from Morningstar Gold Medalist equity funds.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,053.20 | 142.30 | -1.74% |
| CAC 40 | 7,790.71 | 125.37 | -1.58% |
| DAX 40 | 22,163.49 | 298.03 | -1.33% |
| Dow JONES (US) | 42,001.76 | 417.86 | 1.00% |
| FTSE 100 | 8,582.81 | 76.04 | -0.88% |
| HKSE | 23,119.58 | 307.02 | -1.31% |
| NASDAQ | 17,299.29 | 504.75 | -2.84% |
| Nikkei 225 | 35,617.56 | 1,502.77 | -4.05% |
| NZX 50 Index | 12,240.85 | 29.15 | -0.24% |
| S&P 500 | 5,611.85 | 30.91 | 0.55% |
| S&P/ASX 200 | 7,843.40 | 138.60 | -1.74% |
| SSE Composite Index | 3,335.75 | 15.56 | -0.46% |